Evaluation of cardiolipin nanodisks as lipid replacement therapy for Barth syndrome

Barth syndrome (BTHS) is a mitochondrial disorder characterized by cardiomyopathy and skeletal muscle weakness. Disease results from mutations in the tafazzin (TAZ) gene, encoding a phospholipid transacylase. Defective tafazzin activity results in an aberrant cardiolipin (CL) profile. The feasibility of restoring the intracellular CL profile was tested by in vivo administration of exogenous CL in nanodisk (ND) delivery particles. Ninety mg/kg CL (as ND) was administered to doxycycline-inducible taz shRNA knockdown (KD) mice once a week. After 10 weeks of CL-ND treatment, the mice were sacrificed and tissues harvested. Liquid chromatography-mass spectrometry of extracted lipids revealed that CL-ND administration failed to alter the CL profile of taz KD or WT mice. Thus, although CL-ND were previously shown to be an effective means of delivering CL to cultured cells, this effect does not extend to an in vivo setting. We conclude that CL-ND administration is not a suitable therapy option for BTHS.

[1]  R. Ryan,et al.  Cardiolipin and mitochondrial cristae organization. , 2017, Biochimica et biophysica acta. Biomembranes.

[2]  R. Ryan,et al.  Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy , 2017, Lipids.

[3]  F. Hsu,et al.  Exogenous cardiolipin localizes to mitochondria and prevents TAZ knockdown-induced apoptosis in myeloid progenitor cells. , 2015, Biochemical and biophysical research communications.

[4]  E. Bertini,et al.  New clinical and molecular insights on Barth syndrome , 2013, Orphanet Journal of Rare Diseases.

[5]  S. Claypool,et al.  Seven functional classes of Barth syndrome mutation. , 2013, Human molecular genetics.

[6]  D. Stokes,et al.  Tafazzin Knockdown in Mice Leads to a Developmental Cardiomyopathy With Early Diastolic Dysfunction Preceding Myocardial Noncompaction , 2012, Journal of the American Heart Association.

[7]  D. Dale,et al.  The cellular and molecular mechanisms for neutropenia in Barth syndrome , 2012, European journal of haematology.

[8]  B. Byrne,et al.  Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency. , 2011, Human gene therapy.

[9]  R. Ryan.  Nanobiotechnology applications of reconstituted high density lipoprotein , 2010, Journal of nanobiotechnology.

[10]  J. Wansapura,et al.  Cardiac and Skeletal Muscle Defects in a Mouse Model of Human Barth Syndrome* , 2010, The Journal of Biological Chemistry.

[11]  F. Hsu,et al.  Toward total structural analysis of cardiolipins: multiple-stage linear ion-trap mass spectrometry on the [M − 2H + 3Li]+ ions , 2010, Journal of the American Society for Mass Spectrometry.

[12]  R. Houtkooper,et al.  Cardiolipin, the heart of mitochondrial metabolism , 2008, Cellular and Molecular Life Sciences.

[13]  M. Schlame,et al.  The Enzymatic Function of Tafazzin* , 2006, Journal of Biological Chemistry.

[14]  M. Schlame,et al.  Barth syndrome, a human disorder of cardiolipin metabolism , 2006, FEBS letters.

[15]  F. Hsu,et al.  Characterization of cardiolipin as the sodiated ions by positive-ion electrospray ionization with multiple stage quadrupole ion-trap mass spectrometry , 2006, Journal of the American Society for Mass Spectrometry.

[16]  F. Hsu,et al.  Characterization of cardiolipin from Escherichia coli by electrospray ionization with multiple stage quadrupole ion-trap mass spectrometric analysis of [M−2H+Na]− ions , 2006, Journal of the American Society for Mass Spectrometry.

[17]  A. Munnich,et al.  Monolysocardiolipins accumulate in Barth syndrome but do not lead to enhanced apoptosis Published, JLR Papers in Press, April 1, 2005. DOI 10.1194/jlr.M500056-JLR200 , 2005, Journal of Lipid Research.

[18]  E. Groisman,et al.  Structural characterization of cardiolipin by tandem quadrupole and multiple-stage quadrupole ion-trap mass spectrometry with electrospray ionization , 2005, Journal of the American Society for Mass Spectrometry.

[19]  R. Wanders,et al.  Linoleic acid supplementation of Barth syndrome fibroblasts restores cardiolipin levels: implications for treatment. , 2003, Journal of lipid research.

[20]  E. Maestrini,et al.  A novel X-linked gene, G4.5. is responsible for Barth syndrome , 1996, Nature Genetics.

[21]  R. Ryan.  Nanodisks: hydrophobic drug delivery vehicles. , 2008, Expert Opinion on Drug Delivery.

[22]  T. Forte,et al.  Optimized bacterial expression of human apolipoprotein A-I. , 2003, Protein expression and purification.